To improve patient outcomes with innovative diagnostic solutions for acute care and preventive medicine.
Actionable insights in real-time.
Jörg Menten, CEO
SphingoTec's innovative biomarkers have a high potential to change the current standard of care in the diagnosis of critically ill patients. We are passionate about improving patient management and delivering new solutions for unmet clinical needs.
Dr. Angelo Moesslang, CFO
It is our mission to provide real-time diagnostic solutions for critically ill patients and we are excited about the opportunity to help establish personalized diagnostics in daily clinical routine.
Dr. Andreas Bergmann, CSO
We bring innovations to frontline healthcare by developing biomarkers and making them available at the point of care. Our goal is to support clinicians in improving patient outcomes and to reduce mortality in critical care settings.
- Jörg Menten, CEO
- Dr. Angelo Moesslang, CFO
- Dr. Andreas Bergmann, CSO
Kidney function biomarker
Proenkephalin A 119-159 (penKid)
The limitations of the current standard of care diagnostics are well known, thus the need to implement new biomarkers to assist a better management of acute kidney injury. Timely information on kidney function is crucial to early initiate nephro-protective strategies.
SphingoTec GmbH is a privately held company with its headquarter in Hennigsdorf near Berlin and a wholly owned subsidiary in San Diego, CA, USA. The headquarter has a long history of biomarker discovery, development, and validation and is the legal manufacturer of the microtiter plate assays. The German company is leading the global commercialization of the diagnostic solutions with a clear goal: improving patient management and reducing healthcare costs
Nexus Dx Inc., a wholly-owned subsidiary of SphingoTec, located in San Diego, CA, USA, is a global provider of a near-patient testing system and diagnostic solution. Fully compliant to ISO13485:2016 regulations, Nexus Dx is improving patient care by providing the medical community with rapid and reliable information at the point of care, delivering patient information when and where it is needed most.
Nexus IB10 point of care analyzer
The Nexus IB10 point of care (POC) technology provides test results in about 20 minutes and can be flexibly deployed in emergency departments, intensive care units, and other near-patient settings. The Nexus IB10 is an in vitro immunology analyzer that quantitatively measures analytes in whole blood or plasma samples on a consumable disc. The POC platform can perform up to three diagnostic parameters at once. The rapid test portfolio includes commonly used parameters in critical care settings as well as the innovative biomarkers penKid, bio-ADM, and DPP3.
Microtiter plate assay
The innovative biomarkers are available as CE IVD microtiter plate (MTP) assays. The MTP is a standard tool in analytical research and labo- ratories. It is a high throughput solution, allowing the measurement of 41 patient samples at once. SphingoTec’s MTP assays are based on a chemiluminescence sandwich immunoassay technology.
Product launch: CE IVD microtiter plate test for DPP3
SphingoTec is offically certified to DIN EN ISO 13485:2016
The novel biomarkers are introduced in routine measurements in European university hospitals.
Nexus IB10 portfolio marketed through SphingoTec’s distributor network.
Over 100.000 patients have been measured with our biomarker tests.
2019 - 2020
Product launches: CE-IVD point of care tests for penKid, bio-ADM and DPP3.
Financing round: 25 million euro growth capital. Investors: HBM, Wellington Partners and ILB.
SphingoTec acquires Nexus Dx Inc. from Samsung.
CE-IVD microtiter plate tests for penKid and bio-ADM launched.
2011 - 2013
Bio-ADM and penKid product development. First clinical validation.
2003 - 2006
Biomarker discovery (penKid, bio-ADM) and prototype develoment. First patent applications.
SphingoTec GmbH was founded by Dr. Andreas Bergmann.